A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer

A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer

Inhibitory antibodies targeting programmed death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) have resulted in improved outcomes for many patients with metastatic non-small cell lung cancer in (NSCLC) in the second-line setting due to their ability to lead to prolonged anti-tumor immune re...

Full description

Bibliographic Details
Main Authors: Jose M. Pacheco, D. Ross Camidge, Robert C. Doebele, Erin Schenk
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-03-01
Series:Frontiers in Oncology
Subjects:
NSCLC
checkpoint inhibitors
clinical trials
KEYNOTE
CheckMate
IMpower
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00195/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00195/full

Similar Items